Pacira Pharmaceuticals (PCRX) Shares are Down -5.03%

Pacira Pharmaceuticals (PCRX) has risen sharply, recording gains of 10.92% in the past 4 weeks. However, the stock has corrected -5.03% in the past 1 week, providing a good buying opportunity on dips. On a relative basis, the stock has outperformed the S&P 500 by 11.16% in the past 4 weeks, but has underperformed the S&P 500 in the past 1 week.

For the current week, the company shares have a recommendation consensus of Buy. The stock has recorded a twenty day Moving Average of 4.7% and the fifty day Moving Average is 2.87%. Pacira Pharmaceuticals, Inc. has dropped 11.74% during the last three month period . Year-to-Date the stock performance stands at -47.64%.

Pacira Pharmaceuticals (PCRX) : Average target price received by Pacira Pharmaceuticals (PCRX) is $75.57 with an expected standard deviation of $18.98. The most aggressive target on the stock is $109, whereas the most downbeat target is $47. 7 financial analysts are currently covering the stock.


Pacira Pharmaceuticals (NASDAQ:PCRX): stock turned positive on Friday. Though the stock opened at $39.4, the bulls momentum made the stock top out at $40.77 level for the day. The stock recorded a low of $39.21 and closed the trading day at $40.21, in the green by 1.54%. The total traded volume for the day was 599,122. The stock had closed at $39.6 in the previous days trading.

Pacira Pharmaceuticals, Inc. is a specialty pharmaceutical company. The Company is focused on the development, commercialization and manufacture of pharmaceutical products, based on its DepoFoam drug delivery technology, primarily for use in hospitals and ambulatory surgery centers. Its primary focus lies in the development of non-opioid products for postsurgical pain control. DepoFoam is basis for the companys lead product candidate, EXPAREL, a liposome injection of bupivacaine, an amide-type local anesthetic indicated for infiltration into the surgical site to produce postsurgical analgesia. In addition to EXPAREL, DepoFoam is also the basis for its other commercial product, DepoCyt(e), which the Company manufactures for its commercial partners, as well as its other product candidates. The Companys other product candidates include DepoMeloxicam and DepoTranexamic Acid.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.